{"prompt": "['MEIRAGTx', 'Gene Therapy for Achromatopsia (CNGA3)', '5.5.2 Secondary Outcomes', 'The secondary outcomes are measures of the efficacy of the ATIMP; these will be performed on an', 'individual participant basis and will be descriptive in nature.', 'Any improvements in visual function from baseline that are greater than the baseline variation', 'and are sustained for at least two consecutive assessments.', 'Any improvement in retinal function from pre - intervention that is greater than the baseline', 'variation and measurable by electrophysiology (pattern ERG or full-field ERG). Quality of life', 'will be measured by the Impact of Visual Impairment (IVI) questionnaire and the EQ5D-5L and', 'EQ5D-Y, or equivalent as appropriate.', 'CNGA3 MGT012 Protocol version 6.0 16Apr2021', 'Page 44 of 68']['MEIRAGTx', 'CNGA3CNGA3 Gene Therapy trial for Achromatopsia', '5.6', 'Trial Assessments', 'Table 2: Trial assessments', 'Screening', 'Baseline\u00b9,', 'ATIMP', 'D1', 'D3', 'W1', 'W2', 'W4', 'W6', 'W12', 'W24', 'admin', 'Flexibility of schedule (+ days)', '- 9 months', 'Day 0', '+', '+', '+', '+', '+', '+', '+', '+ 14D', 'OD', '1D', '2D', '4D', '7D', '7D', '14D', 'Visit number', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', 'Informed consent', 'Physical exam', '.', 'Medical history', 'Eligibility determination', 'ATIMP administration', 'Adverse event review', 'Concomitant medication review', 'Genetic screening2', 'Pregnancy test', 'Vital signs\u00b3', 'Haematology4', 'Biochemistry/glucose/liver and renal function5', 'Serology', 'PCR', 'QoL questionnaires (IVI and EQ5D-5L, or', 'equivalent)', 'Visual acuity6', 'Colour vision assessments', 'Contrast sensitivity', 'Reading assessments', 'Static perimetry', 'Full Field Stimulus Testing', 'Ocular examination', 'CNGA3 MGT012 Protocol version 6.0 16Apr 2021', 'Page 45 of 68']['MEIRAGTx', 'CNGA3CNGA3 Gene Therapy trial for Achromatopsia', 'Screening', 'Baseline\u00b9', 'ATIMP', 'D1', 'D3', 'W1', 'W2', 'W4', 'W6', 'W12', 'W24', 'admin', 'Flexibility of schedule (+ days)', '- 9 months', 'Day 0', '+', '+', '+', '+', '+', '+', '+', '+ 14D', 'OD', '1D', '2D', '4D', '7D', '7D', '14D', 'Fundus photography', 'Optical coherence tomography', 'Adaptive optics imaging', 'Fundus autofluorescence', 'Pattern Electroretinography?', 'Full field Electroretinography7', 'Photoaversion/ light sensitivity assessments', '8', '8', '8', '9', '9', '(test and questionnaires)', '1', 'Baseline assessments may be performed on the same day where considered logistically and clinically appropriate', '2 If result is available from prior testing, no repeat test mandated. Result will be reported into the CRF.', '3 Measurements for vital signs include: blood pressure, pulse, respiration rate, arterial oxygen saturation, temperature, height and weight', '4 Hematology to include the following parameters: Haemoglobin, Haematocrit, Erythrocytes, Mean Corpuscular Volume, Mean Corpuscular Haemoglobin, Platelet,', 'Leukocytes, Absolute Neutrophils, Absolute Lymphocytes, Absolute Neutrophils, Absolute Eosinophils, Absolute Basophils', '5 Biochemistry to include the following parameters: Sodium, Potassium, Chloride, Bilirubin, Alkaline Phosphatase, Aspartate Aminotransferase, Alanine, Aminotransferase,', 'Lactate Dehydrogenase, Gamma Glutamyl Transferase, Total Protein, Albumin, Calcium, Magnesium, Phosphate, Urea/BUN, Urate, Creatinine,', 'Glucose', '6', 'Visual acuity at day 1 and 3 will be assessed using the previous refraction.', '7', 'ERG assessments may be performed under general anaesthesia if necessary.', '8 Photoaversion Questionnaire only to be completed at one baseline visit, \"Photoaversion Device Questionnaire - Baseline\" to be completed after every PA assessment', '9 \"Photoaversion Device Questionnaire - after Surgery\" to be used at week 12 and week 24 straight after Photoaversion assessments.', 'For management of visits delayed due to COVID_19 refer to appendix.', 'CNGA3 MGT012 Protocol version 6.0 16Apr2021', 'Page 46 of 68']\n\n###\n\n", "completion": "END"}